# Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

> **NCT00267553** · PHASE3 · TERMINATED · sponsor: **Intarcia Therapeutics** · enrollment: 200 (—)

## Conditions studied

- Breast Neoplasms
- Neoplasms, Hormone-Dependent

## Interventions

- **DRUG:** Atamestane
- **DRUG:** toremifene
- **DRUG:** letrozole

## Key facts

- **NCT ID:** NCT00267553
- **Lead sponsor:** Intarcia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-11
- **Primary completion:** —
- **Final completion:** 2006-06
- **Target enrollment:** 200 (—)
- **Why stopped:** This was a follow-on study to Biomed 777-CLP-029 which did not meet superiority endpoint
- **Last updated:** 2007-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00267553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00267553, "Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00267553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*